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Abstract
Background: Nuclear protein in testis (NUT) midline carcinoma is a rarely diagnosed and potentially under-
recognized type of squamous carcinoma that is considered one of the most aggressive human solid tumors.
Alpha-fetoprotein elevation has been associated with chronic liver diseases and a limited number of cancers.
In particular, in presence of a mediastinal mass in a young man, alpha-fetoprotein elevation is considered
nearly pathognomonic of a non-seminoma germ-cell tumor.
Case presentation: A 22-year old man without any comorbidity was diagnosed with a large mediastinal
mass with skeletal and lymph node metastases. The clinical picture was dominated by a life-threatening
superior vena cava syndrome with elevated alpha-fetoprotein and lactate dehydrogenase that supported
the diagnostic suspicion of mediastinal germ-cell tumor. However, a biopsy showed a poorly-differentiated
and diffusely necrotic carcinoma. We eventually reached the diagnosis of the peculiar entity of NUT midline
carcinoma, but the differential diagnosis was quite challenging also because alpha-fetoprotein is not reported
as a marker of NUT midline carcinoma. Notably, alpha-fetoprotein levels correlated with disease course.
Conclusions: The life-threatening aggressiveness of NUT midline carcinoma mandates to reach the right
diagnosis in the shortest possible time. In this regard, poorly differentiated carcinomas lacking glandular
differentiation mandate testing for NUT expression by immunohistochemistry. Awareness of a potentially
misleading tumor marker elevation can help to broaden the differential diagnosis and establish the most
appropriate treatment.
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Background
Nuclear protein in testis (NUT) midline carcinoma is an
exceedingly rare subtype of squamous poorly–differenti-
ated carcinoma and is considered one of the most
aggressive human solid tumors [1–3]. NUT midline car-
cinoma is a relatively new entity, that may likely be
under–recognized and under–diagnosed. All ages and
organs might be affected, but most frequently NUT mid-
line carcinoma arises along the trunk or the head and, in
particular, in midline structures such as the mediastinum
[1–3]. NUT midline carcinoma is characterized by the
pathognomonic chromosomal rearrangement between
the NUT gene with either bromodomain–containing
protein 4 (BRD4) or, less frequently, with BRD3 (on
chromosome 9), leading to the fusion genes BRD4–NUT
or BRD3–NUT, respectively [1–3]. BRD is a DNA reader
that activates transcription by binding to acetyl–modi-
fied lysine residues of histone tails [1, 3, 4]. The expres-
sion of several oncogenes, including transcription factors
and MYC, is epigenetically regulated by BRD. More
recently, a novel fusion gene between the methyl-
transferase protein NSD3 on chromosome 8 and NUT
has been reported (NSD3–NUT) [1, 5, 6]. NSD3 has
shown to be associated with the extraterminal domains of
BET proteins, which serves as a key component in the
BRD–NUT oncogene complex [1]. Moreover, two novel
three–way translocations [t(9;15;19;q34;q13;p13.1), and
t(4;15;19)(q13;q14;p13.1)] have been described [5, 6].
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NUT rearrangement has been suggested to possi-
bily represent a tumor–initiating event. Its importance
in the pathogenesis of NUT midline carcinoma is fur-
ther supported by the evidences that withdrawal of
the NUT fusion protein resulted in a dramatic and ir-
reversible squamous differentiation and growth arrest,
thus demonstrating that the BRD–NUT protein
blocks differentiation [7].
Alpha–fetoprotein elevation has been associated with
chronic liver diseases and a limited number of cancers
(hepatic primary tumors and metastases, bile duct, pan-
creatic, gastric and lung cancer, and non–seminoma
germ–cell tumors). Moreover, in presence of testicular
or mediastinal mass an elevated alpha–fetoprotein
strongly suggests a non–seminoma germ–cell tumor
especially in young patients.
Case presentation
A 22–year old man was referred to our center because
of a large mediastinal mass along with skeletal and
lymph node metastases. The clinical picture was domi-
nated by shortness of breath due to severe superior vena
cava syndrome with pleural–pericardial effusion (Fig. 1
panels a, b, c). Laboratory tests showed elevated alpha–
fetoprotein (765 ng/mL; normal value <10.9 ng/mL) and
lactate dehydrogenase (LDH) = 14,468 U/L (normal
range 240–480 U/L). Taken altogether these findings
strongly suggested a mediastinal non–seminoma germ
cell tumor (GCT) [7] but, unexpectedly, a biopsy of a
supraclavicular enlarged lymph node revealed a poorly
differentiated and diffusely necrotic carcinoma (Fig. 2,
panels a, b). Immunohistochemistry was weakly positive
for AE1–AE3 cytokeratin pool, TTF–1, p63, synaptophy-
sin, chromogranin A, CD34 and, focally, EMA and cyto-
keratin 7, but negative for PLAP, alpha–fetoprotein,
beta–HCG, CD30, CD3, CD20, CD117, Melan–A, S100
protein, ALK, PAX8, and desmin, thereby ruling out
GCT (Table.1 describes detailed immunohistochemistry
profile and clues to diagnosis suggested by each immu-
nohistochemical marker) [7]. Due to such peculiar pres-
entation and the high levels of alpha–fetoprotein, a
second pathology opinion was requested. GCT was
again excluded and a diagnosis of poorly differentiated
large cell carcinoma with neuroendocrine differentiation
was rendered. However, taking advantage of the clinical
presentation and the patient’s young age, in a third con-
sultation, a monoclonal antibody against NUT protein
was used (Fig. 2, panel c) [8] along with fluorescence
in situ hybridization (FISH) analysis for NUT–BRD4
translocation [3]. Tumor cells revealed diffuse decor-
ation for NUT protein and FISH analysis confirmed
the occurrence of t(15;19) BRD4–NUT translocation
(Fig. 2 panel d), thereby establishing the diagnosis of
NUT midline carcinoma [1, 3].
Notably, in our patient alpha–fetoprotein levels dir-
ectly correlated with disease course. Indeed, in this
young gentleman, basal level was 765 u/mL and de-
clined to 505 u/mL after two chemotherapy cycles
(cisplatin 25 mg/m2 days 1- > 4, etoposide 100 mg/
m2 days 1- > 4) along with a sharp clinical improve-
ment due to attenuation of the superior vena cava
syndrome. Unfortunately, clinical benefit was short–
lasting and alpha–fetoprotein rose up again at the
time of subsequent disease progression (Fig. 3).
Discussion and conclusions
Diagnosis of NUT midline carcinoma is quite challen-
ging and demands to be hypothesized and specifically
demonstrated. Indeed, microscopic features are quite
unspecific and range from completely undifferentiated
carcinoma to carcinoma with squamous differentiation
and abrupt keratinization that may be either focal or
Fig. 1 Disease status at diagnosis. Panel a, c: CT scan showing
bulky mediastinal mass with involvemente of right lung ilum,
compression of the right superior bronchus, and dislocation of
the trachea and right intermediate bronchus with pleural and
pericardial effusion (panel a axial, panel c sagittal). Panel b: PET
scan showing supraclavicular involvement of the disease and
absence of liver metastases. CT, computed tomography; PET
positron emission tomography
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prominent. Tumor cells usually have an epithelioid,
medium–size appearance and are in general mono-
morphic with round to oval nuclei and distinct nucleoli.
Further morphologic aspects are a high mitotic rate
along with necrosis and neutrophilic infiltrates. Immu-
nohistochemistry with the NUT antibody is positive with
a diffuse nuclear staining. However, NUT positivity
might be found in GCTs as well and, to be regarded as
truly positive, it must be seen in >50% of tumor cells.
Another peculiarity of NUT midline carcinoma is
represented by the relatively simple karyotype that often
presents the NUT translocation as the only relevant ab-
normality. This strongly differentiate this tumor from
other squamous cell carcinomas that usually harbor
highly aberrant and complex karyotypes [9, 10].
Differential diagnosis includes several tumors, encom-
passing hematologic malignancies or neuroendocrine tu-
mors, because of non–specific morphology and
immunohistochemistry profile apart from the pathogno-
monic NUT protein expression and the characteristic
cytogenetic abnormalities [1, 3, 11]. As a general rule, it
is recommended to perform immunohistochemistry for
NUT protein in all poorly differentiated carcinomas that
lack glandular differentiation and whenever the clinical
picture is not completely consistent with more frequent
tumors (midline or unusual position, young people, no
smoking habit, rapid progression upon therapy) [2, 8, 12].
Both clinical history and some pathologic features (i.e.,
monomorphic tumor cells with abrupt keratinization)
might help in generating the suspicion of NUT midline
carcinoma. [10–12].
In the absence of hepatic involvement (Fig. 1 panel c),
the diagnosis of NUT midline carcinoma was particu-
larly challenging in our patient because alpha–fetopro-
tein has only seldom been reported associated with this
tumor [1, 3, 13–16]. Table 2 describes other clinical
cases reporting alpha–fetoprotein elevation. Moreover,
in NUT midline carcinoma immunohistochemical ex-
pression of alpha-fetoprotein is negative, as it was in our
patient and in other NUT midline carcinoma cases de-
scribing serum alpha-fetoprotein elevation [1, 3, 17].
Interestingly, alpha–fetoprotein levels during treatment
were not reported in the majority of the cases, whereas
this marker correlated with disease course in our pa-
tient. In light of these findings, we suggest not to ex-
clude and, on the contrary, to take into consideration
the diagnosis of NUT midline carcinoma when facing
a patient with fast–growing lump in midline struc-
tures and alpha-fetoprotein elevation. Of course,
evaluation of alpha–fetoprotein levels in other cases of
NUT midline carcinoma might help to better define the
role of this serum marker in this challenging disease.
The observed elevation of alpha–fetoprotein in NUT
midline carcinoma might be related to the suggested
Fig. 2 Pathology images. Panel a, b: Hematoxilin and eosin stain
(panel a 20X magnification, panel b 40X magnification). NUT
carcinoma typically shows sheets of monomorphic round to ovoid
cells with scant pale eosinophilic to basophilic cytoplasm; nuclei
with irregular outlines and slightly coarse chromatin with small
nucleoli. Necrosis, mitotic figures and crush artefact are common.
Panel c: diffuse nuclear immunohistochemical staining with nuclear
protein in testis (NUT) antibody (40X magnification). NUT (C52B1,
CELL Signaling, Technology) Rabbit mAb detects endogenous levels
of total NUT protein. The antibody also detects levels of BRD4-Nut
fusion protein. Panel d: FISH showing positivity for NUT-BRD4 fusion
gene. FISH was performed using dual color single fusion probes:
BAC clone (RP11-122P18) spanning NUT gene is labeled in spectrum
orange, BAC clone RP11-637P24 covering BRD4 gene is labeled in
spectrum green. The presence of the translocation t (15;19)(q14;p13)
BRD4/NUT is showed by overlapping of one green and one orange
probe signal (white arrows). FISH, fluorescence in situ hybridization;
NUT, nuclear protein in testis; BRD4, bromodomain–containing
protein–4; BAC, bacterial artificial chromosome
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hypothesis that these cells arise from primitive neural
crest–derived cells. [9] Indeed, both gene expression
profile similar to adult ciliary ganglion [18] and the ab-
sence of the in-situ component are consistent with this
cell of origin. [7].
Beyond its rarity, NUT midline carcinoma may ini-
tially and transiently respond to several cytotoxics [2]
used to treat undifferentiated carcinomas, making even
less likely the raising of the right diagnostic suspicion.
Regardless the chosen treatment, activity was at most
transient and short–lasting [2]. Therefore, to reach the
correct diagnosis in the shortest possible time is crucial
because prognosis is dismal, clinical conditions may
worsen in few days, conventional chemotherapy is only
Table 1 Immunohistochemistry profile at the time of first evaluation
Weakly positive Clues to diagnosis (if positive) Negative Clues to diagnosis (if positive)
AE1-AE3 cytokeratin pool Carcinomas, GCT (rare), thymoma, mesenchymal
tumors
PLAP Seminoma
TTF-1 Lung, thyroid cancer AFP Non-seminoma GCT, HCC, pancreas carcinoma
p63 Basal/squamous carcinoma, mesenchymal tumors,
lymphomas, adenoid cystic carcinoma, salivary
gland tumors, thymoma, thymic carcinoma, breast,
urothelial carcinoma
Beta-HCG Non-seminoma GCT
Synaptophysin Neuroendocrine neoplasms, adrenal gland
carcinoma, mesenchymal tumors
CD30 Lymphomas (HL and NHL), non-seminoma GCT,
Chromogranin A Neuroendocrine tumors CD3 T-cell lymphomas
CD34 Hematologic malignances, mesenchymal tumors,
papillary thyroid carcinoma, thymoma
CD20 B-cell lymphomas
Focally positive CD117 Mesenchymal tumors, GCT, SCLC, leukemias,
lymphomas, melanoma
EMA adenocarcinoma, renal cell carcinoma,
choriocarcinoma, mesenchymal tumors,
mesothelioma, lymphoma, thymic carcinoma
Melan-A Melanoma, mesenchymal tumors, adrenal
cortical tumors, sex-cord stromal tumors
Cytokeratin 7 Lung cancer and other carcinomas, GCT (rare),
mesenchymal tumors
S-100 Melanoma, mesenchymal tumors, adenoid
cystic carcinoma, sex-cord stromal tumors
ALK Lymphomas, NSCLC, mesenchymal tumors,
RCC (rare)
PAX8 Thymic carcinoma, thymomas, thyroid
anaplastic carcinoma, RCC, neuroendocrine
neoplasms, seminoma
Desmin Mesenchymal tumors
TTF-1 thyroid transcription factor-1, EMA epithelial membrane antigen, PLAP placental alkaline phosphatase, AFP alpha-fetoprotein, beta-HCG human chorionic
gonadotropin, ALK anaplastic lymphoma kinase, GCT germ cell tumor, HCC hepatocellular carcinoma, HL Hodgkin’s lymphoma, NHL Non-Hodgkin lymphoma,
RCC renal cell carcinoma, SCLC small cell lung cancer, NSCLC non-small cell lung cancer
Fig. 3 Alpha-fetoprotein levels and disease course during chemotherapy
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marginally active and, finally, a new target therapy based
on bromodomain inhibitors is showing promising results
[4, 19, 20]. Despite being an experimental treatment,
patients should be strongly encouraged to enroll in clin-
ical trials to rapidly explore these innovative therapeutic
strategies.
In conclusion, to avoid misleading diagnostic inter-
pretation in case of alpha–fetoprotein elevation, sharing
patient information between pathologists and clinicians
assessing patients affected by poorly differentiated car-
cinoma arising nearby midline structures is crucial and
we point out to consider NUT midline carcinoma in the
differential diagnosis. Finally, in light of our observation,
we also suggest to measure alpha–fetoprotein levels
during tumor treatment to monitor disease course.
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